Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease

Sirous Darabian, Manoch Rattanasompattikul, Parta Hatamizadeh, Suphamai Bunnapradist, Matthew J. Budoff, Csaba Kovesdy, Kamyar Kalantar-Zadeh

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Cardiorenal syndrome (CRS) refers to a constellation of conditions whereby heart and kidney diseases are pathophysiologically connected. For clinical purposes, it would be more appropriate to emphasize the pathophysiological pathways to classify CRS into: (1) hemodynamic, (2) atherosclerotic, (3) uremic, (4) neurohumoral, (5) anemic-hematologic, (6) inflammatory-oxidative, (7) vitamin D receptor (VDR) and/or FGF23-, and (8) multifactorial CRS. In recent years, there have been a preponderance data indicating that vitamin D and VDR play an important role in the combination of renal and cardiac diseases. This review focuses on some important findings about VDR activation and its role in CRS, which exists frequently in chronic kidney disease patients and is a main cause of morbidity and mortality. Pathophysiological pathways related to suboptimal or defective VDR activation may play a role in causing or aggravating CRS. VDR activation using newer agents including vitamin D mimetics (such as paricalcitol and maxacalcitol) are promising agents, which may be related to their selectivity in activating VDR by means of attracting different post-D-complex cofactors. Some, but not all, studies have confirmed the survival advantages of D-mimetics as compared to non-selective VDR activators. Higher doses of D-mimetic per unit of parathyroid hormone (paricalcitol to parathyroid hormone ratio) is associated with greater survival, and the survival advantages of African American dialysis patients could be explained by higher doses of paricalcitol (>10 μg/week). More studies are needed to verify these data and to explore additional avenues for CRS management via modulating VDR pathway.

Original languageEnglish (US)
Pages (from-to)12-25
Number of pages14
JournalKidney Research and Clinical Practice
Volume31
Issue number1
DOIs
StatePublished - Mar 1 2012

Fingerprint

Cardio-Renal Syndrome
Calcitriol Receptors
Chronic Renal Insufficiency
Parathyroid Hormone
Vitamin D
Survival
Heart Diseases
Kidney Diseases
African Americans
Dialysis
Hemodynamics
Morbidity
Kidney

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Urology

Cite this

Darabian, S., Rattanasompattikul, M., Hatamizadeh, P., Bunnapradist, S., Budoff, M. J., Kovesdy, C., & Kalantar-Zadeh, K. (2012). Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease. Kidney Research and Clinical Practice, 31(1), 12-25. https://doi.org/10.1016/j.krcp.2011.12.006

Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease. / Darabian, Sirous; Rattanasompattikul, Manoch; Hatamizadeh, Parta; Bunnapradist, Suphamai; Budoff, Matthew J.; Kovesdy, Csaba; Kalantar-Zadeh, Kamyar.

In: Kidney Research and Clinical Practice, Vol. 31, No. 1, 01.03.2012, p. 12-25.

Research output: Contribution to journalReview article

Darabian, S, Rattanasompattikul, M, Hatamizadeh, P, Bunnapradist, S, Budoff, MJ, Kovesdy, C & Kalantar-Zadeh, K 2012, 'Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease', Kidney Research and Clinical Practice, vol. 31, no. 1, pp. 12-25. https://doi.org/10.1016/j.krcp.2011.12.006
Darabian, Sirous ; Rattanasompattikul, Manoch ; Hatamizadeh, Parta ; Bunnapradist, Suphamai ; Budoff, Matthew J. ; Kovesdy, Csaba ; Kalantar-Zadeh, Kamyar. / Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease. In: Kidney Research and Clinical Practice. 2012 ; Vol. 31, No. 1. pp. 12-25.
@article{90ab7c5f1c7742c790e4eaaa17490fc7,
title = "Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease",
abstract = "Cardiorenal syndrome (CRS) refers to a constellation of conditions whereby heart and kidney diseases are pathophysiologically connected. For clinical purposes, it would be more appropriate to emphasize the pathophysiological pathways to classify CRS into: (1) hemodynamic, (2) atherosclerotic, (3) uremic, (4) neurohumoral, (5) anemic-hematologic, (6) inflammatory-oxidative, (7) vitamin D receptor (VDR) and/or FGF23-, and (8) multifactorial CRS. In recent years, there have been a preponderance data indicating that vitamin D and VDR play an important role in the combination of renal and cardiac diseases. This review focuses on some important findings about VDR activation and its role in CRS, which exists frequently in chronic kidney disease patients and is a main cause of morbidity and mortality. Pathophysiological pathways related to suboptimal or defective VDR activation may play a role in causing or aggravating CRS. VDR activation using newer agents including vitamin D mimetics (such as paricalcitol and maxacalcitol) are promising agents, which may be related to their selectivity in activating VDR by means of attracting different post-D-complex cofactors. Some, but not all, studies have confirmed the survival advantages of D-mimetics as compared to non-selective VDR activators. Higher doses of D-mimetic per unit of parathyroid hormone (paricalcitol to parathyroid hormone ratio) is associated with greater survival, and the survival advantages of African American dialysis patients could be explained by higher doses of paricalcitol (>10 μg/week). More studies are needed to verify these data and to explore additional avenues for CRS management via modulating VDR pathway.",
author = "Sirous Darabian and Manoch Rattanasompattikul and Parta Hatamizadeh and Suphamai Bunnapradist and Budoff, {Matthew J.} and Csaba Kovesdy and Kamyar Kalantar-Zadeh",
year = "2012",
month = "3",
day = "1",
doi = "10.1016/j.krcp.2011.12.006",
language = "English (US)",
volume = "31",
pages = "12--25",
journal = "Kidney Research and Clinical Practice",
issn = "2211-9132",
publisher = "Elsevier Korea",
number = "1",

}

TY - JOUR

T1 - Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease

AU - Darabian, Sirous

AU - Rattanasompattikul, Manoch

AU - Hatamizadeh, Parta

AU - Bunnapradist, Suphamai

AU - Budoff, Matthew J.

AU - Kovesdy, Csaba

AU - Kalantar-Zadeh, Kamyar

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Cardiorenal syndrome (CRS) refers to a constellation of conditions whereby heart and kidney diseases are pathophysiologically connected. For clinical purposes, it would be more appropriate to emphasize the pathophysiological pathways to classify CRS into: (1) hemodynamic, (2) atherosclerotic, (3) uremic, (4) neurohumoral, (5) anemic-hematologic, (6) inflammatory-oxidative, (7) vitamin D receptor (VDR) and/or FGF23-, and (8) multifactorial CRS. In recent years, there have been a preponderance data indicating that vitamin D and VDR play an important role in the combination of renal and cardiac diseases. This review focuses on some important findings about VDR activation and its role in CRS, which exists frequently in chronic kidney disease patients and is a main cause of morbidity and mortality. Pathophysiological pathways related to suboptimal or defective VDR activation may play a role in causing or aggravating CRS. VDR activation using newer agents including vitamin D mimetics (such as paricalcitol and maxacalcitol) are promising agents, which may be related to their selectivity in activating VDR by means of attracting different post-D-complex cofactors. Some, but not all, studies have confirmed the survival advantages of D-mimetics as compared to non-selective VDR activators. Higher doses of D-mimetic per unit of parathyroid hormone (paricalcitol to parathyroid hormone ratio) is associated with greater survival, and the survival advantages of African American dialysis patients could be explained by higher doses of paricalcitol (>10 μg/week). More studies are needed to verify these data and to explore additional avenues for CRS management via modulating VDR pathway.

AB - Cardiorenal syndrome (CRS) refers to a constellation of conditions whereby heart and kidney diseases are pathophysiologically connected. For clinical purposes, it would be more appropriate to emphasize the pathophysiological pathways to classify CRS into: (1) hemodynamic, (2) atherosclerotic, (3) uremic, (4) neurohumoral, (5) anemic-hematologic, (6) inflammatory-oxidative, (7) vitamin D receptor (VDR) and/or FGF23-, and (8) multifactorial CRS. In recent years, there have been a preponderance data indicating that vitamin D and VDR play an important role in the combination of renal and cardiac diseases. This review focuses on some important findings about VDR activation and its role in CRS, which exists frequently in chronic kidney disease patients and is a main cause of morbidity and mortality. Pathophysiological pathways related to suboptimal or defective VDR activation may play a role in causing or aggravating CRS. VDR activation using newer agents including vitamin D mimetics (such as paricalcitol and maxacalcitol) are promising agents, which may be related to their selectivity in activating VDR by means of attracting different post-D-complex cofactors. Some, but not all, studies have confirmed the survival advantages of D-mimetics as compared to non-selective VDR activators. Higher doses of D-mimetic per unit of parathyroid hormone (paricalcitol to parathyroid hormone ratio) is associated with greater survival, and the survival advantages of African American dialysis patients could be explained by higher doses of paricalcitol (>10 μg/week). More studies are needed to verify these data and to explore additional avenues for CRS management via modulating VDR pathway.

UR - http://www.scopus.com/inward/record.url?scp=84879193301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879193301&partnerID=8YFLogxK

U2 - 10.1016/j.krcp.2011.12.006

DO - 10.1016/j.krcp.2011.12.006

M3 - Review article

VL - 31

SP - 12

EP - 25

JO - Kidney Research and Clinical Practice

JF - Kidney Research and Clinical Practice

SN - 2211-9132

IS - 1

ER -